The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization

Verified by: University of Oklahoma, September 2011
First Received: March 24, 2008 | Last Updated: September 7, 2011 | Phase: N/A | Start Date: March 2007
Overall Status: Completed | Estimated Enrollment: 27
  • …
  • Tell a FriendPrint

This study will explore the effect of clopidogrel on coated-platelets in patients who are given a loading dose before diagnostic catheterization or percutaneous coronary intervention. We hypothesis that clopidogrel will reduce the percentage of platelets that are coated and therefore more hypercoagulable...

Brief Summary

Official Title: “The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization”

This study will explore the effect of clopidogrel on coated-platelets in patients who are given a loading dose before diagnostic catheterization or percutaneous coronary intervention. We hypothesis that clopidogrel will reduce the percentage of platelets that are coated and therefore more hypercoagulable.

  • Study Type: Interventional
  • Study Design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
  • Study Primary Completion Date: September 2008

Detailed Clinical Trial Description

Platelet activity will be determined by light transmission aggregometry at baseline, after a 300 mg dose of clopidogrel and after the catheterization and/or angioplasty procedure. The change in the percentage of platelets that are coated platelets will be determined.

Intervention(s) in this Clinical Trial

  • Drug: Clopidogrel
    • All subjects will receive a 300 mg loading dose

Outcome Measures for this Clinical Trial

Primary Measures

  • The Percentage of Coated Platelets After the Administration of Clopidogrel in Patients Undergoing Cardiac Catheterization and/or Angioplasty
    • Time Frame: 24 hours after the administration of clopidotrel
      Safety Issue?: No

Secondary Measures

  • The Percentage of Coated Platelets After Coronary Angiography and/or PCI
    • Time Frame: 6 hrs after procedure
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • Patients given clopidogrel loading dose before scheduled catheterization or percutaneous intervention

Exclusion Criteria:

  • Acute coronary syndrome
  • Unable to tolerate clopidogrel

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 65 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Investigator Information

Lead Investigator: University of Oklahoma Other

Overall Clinical Trial Officials and Contacts

Eliot Schechter, MD Principal Investigator University of Oklahoma  

Additional Information

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00644657

Study ID Number: 13291

ClinicalTrials.gov Identifier: NCT00644657

Health Authority: United States: Institutional Review Board

  • …
  • Tell a FriendPrint

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00644657